Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.
You may also be interested in...
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
BIO CEO & Investor Conference In Brief
CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said